Kymera Therapeutics’ chief medical officer sells shares worth $174,785

WATERTOWN, MA—Kymera Therapeutics, Inc. (NASDAQ:KYMR) Chief Medical (TASE:BLWV) Officer Jared Gollob recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On March 3, Gollob sold a total of 5,740 shares of common stock in two separate transactions. The shares were sold at prices ranging from $30.3271 to $31.0046, generating a total of $174,785. The sales come as the stock has declined nearly 15% over the past week and trades near its 52-week low of $29.16, according to InvestingPro data.

In addition to the sales, Gollob acquired 30,000 restricted stock units (RSUs) on the same day. These RSUs represent a contingent right to receive one share of the company’s common stock upon vesting and will vest in three equal annual installments starting March 3, 2025, contingent upon his continued employment.

Furthermore, Gollob was granted stock options for 60,000 shares, which will vest in 36 equal monthly installments following March 3, 2025, provided he remains employed with the company.

Following these transactions, Gollob holds a total of 120,000 shares in Kymera Therapeutics.

In other recent news, Kymera Therapeutics reported its fourth-quarter 2024 financial results, which did not meet analyst expectations. The company experienced a loss of $0.88 per share, surpassing the anticipated $0.77 loss per share. Revenue for the quarter was $7.39 million, significantly below the expected $14.71 million. In addition, collaboration revenues dropped to $7.4 million from $47.9 million the previous year, attributed entirely to the partnership with Sanofi (NASDAQ:SNY). Despite these financial setbacks, Kymera maintains a robust financial position with $851 million in cash reserves, projected to support operations until mid-2027. Truist Securities reaffirmed a Buy rating for Kymera, maintaining a $53 price target, citing confidence in the company’s technology and management. H.C. Wainwright also maintained a Buy rating but adjusted the price target from $60 to $54, reflecting a cautious yet optimistic view of ongoing clinical trials. Kymera has announced a new performance-based stock plan to align employee incentives with clinical milestones, underscoring its commitment to advancing its clinical programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.